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Abstract Although several observations suggest that a
strong genetic predisposition to developing testicular germ
cell tumors (TGCT) exists, no associated, highly penetrant
germline mutations have been identiﬁed so far. In the 129/
Sv mouse strain, a germline mutation in the DND1 gene
has been shown to strongly increase the TGCT risk. We
screened 272 men with TGCT (89% sporadic cases, 11%
familial) for germline mutations in the human homologue
of DND1. A single nucleotide substitution c.657C[G
(p.Asp219Glu) was observed in a non-familial case of
testicular embryonal carcinoma. The variant was also
present in the patient’s asymptomatic father and two
brothers, but not observed in 210 control chromosomes.
The wild type DND1 allele was not lost in the patient’s
tumor. In silico analysis of the variant predicts it to be non-
pathogenic. We conclude that germline DND1 mutations
are unlikely to contribute signiﬁcantly to human testicular
germ cell tumor susceptibility. The role of human DND1 in
normal physiology and disease, however, is still virtually
unknown and it therefore warrants further research.
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Introduction
A family history of testicular germ cell tumors (TGCT) is a
strong risk factor for developing this tumor type [1].
Although low to mild penetrant gene variants have been
identiﬁed, including cKIT mutations [2], linkage analysis,
genome-wide association studies and a candidate gene
approach have not yet been successful in identifying highly
penetrant germline mutations as the cause of familial
TGCT [3–7]. Animal models may help to identify disease-
predisposing mutations in humans, for example, in the 129/
Sv mouse model, a germline mutation in DND1 (Dead-
end 1) has been shown to cause TGCT [8]. Although the
tumors in the mouse model resemble the germ-cell tumors
that occur in human infants rather than in adults [9, 10],
this does not necessarily indicate that a role for the human
orthologue of DND1 in TGCT development would be
restricted to that histological subtype. A recent study, the
ﬁrst to analyze germline human DND1 (MIM 609385) in a
clinical disorder, therefore screened the gene for mutations
in a series of 263 familial and sporadic TGCT patients and
found a possibly pathogenic missense p.Glu86Ala mutation
in a single case [11]. These ﬁndings could neither conﬁrm
nor reject a role for germline DND1 mutations in human
TGCT. We therefore searched for germline DND1 muta-
tions in an independent set of sporadic and familial cases of
testicular cancer.
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Patients
From the 1,113 patients treated for TGCT at the University
Medical Center Groningen (UMCG) between 1977 and
2001, we included 30 known familial cases (2.7% of total)
and randomly selected 242 sporadic cases in this study.
Familial cases were deﬁned as those patients with one or
more reported ﬁrst- or second-degree relatives with TGCT.
In the patients selected for our study, non-seminomas had
been diagnosed in 215 of the sporadic cases (88% of all
sporadic cases) and in 23 of the familial cases (77% of all
familial cases). Seminomas had been diagnosed in 27
sporadic cases (12% of all sporadic cases) and in 7 familial
cases (23% of all familial cases). All patients gave
informed consent for this study, which was approved by the
UMCG’s institutional review board.
Controls
We tested 210 control chromosomes for any DND1 variant
we detected in the patients if it was not reported as a
common polymorphism in NCBI dbSNP (http://www.ncbi.
nlm.nih.gov/projects/SNP/).
Screening of DND1
DNA was isolated from peripheral blood lymphocytes
using standard methods. Denaturing gradient gel electro-
phoresis (DGGE, technique reported elsewhere [12] was
used to screen DND1 exons 2 and 4, and part of exon 3 for
mutations. If there were abnormal bands, the amplicons in
question were sequenced. Exon 1 and the 3’ site of exon 3
were fully sequenced. DGGE and sequencing primers are
listed in Table 1. Reference sequence used: GenBank
accession number NM_194249.
Variant analysis
Any variant detected, excluding the common SNPs, was
analyzed in silico using three sequence homology-based
programmes: Align-GVGD (http://agvgd.iarc.fr/agvgd_
input.php), PolyPhen (Polymorphism Phenotyping, http://
genetics.bwh.harvard.edu/pph/) and Sorting Intolerant from
Tolerance (SIFT, http://blocks.fhcrc.org/sift/SIFT.html).
Thepossibleeffectonthefunctionofthespliceacceptorsite,
the splice donor site, or creation of a novel splice site was
analyzed by using tools from Netgene (http://www.cbs.
dtu.dk/services/NetGene2/) and the Berkeley Drosophila
Genome Project (http://www.fruitﬂy.org/seq_tools/splice.
html).
Loss-of-heterozygosity analysis
One patient was found to have an exon 4 missense muta-
tion (see ‘‘Results’’ section) so the parafﬁn blocks of his
tumor were sampled for DNA extraction and subsequent
sequencing of the relevant part of DND1 to search for loss
of heterozygosity. Three samples were tested: one from his
testicular teratoma, one from a neighboring carcinoma in
situ, and one from his normal testicular tissue. His healthy
parents and two healthy adult brothers were also analyzed
for the presence of the missense mutation by direct
sequencing.
Results
In exon 4 of DND1 we observed a single base substitution
c.657C[G (p.Asp219Glu) (Fig. 1) in a 31-year-old
patient who had been diagnosed with a non-familial case of
non-seminoma at the age of 18 years. This patient had an
Table 1 Primers used for analyzing DND1
Exon 1-F: [M13-F]GTCGCGCTCAGAGCCAATG
Exon1-R: [M13-R]CTTCCTCTGCCCGTTCACC
Product size 362 Bps
Exon2-F: [60GC]TCCGCCATTCCAACCTTCCTT
Exon2-R: AAAGGGGGCTGGTGTAGCCG
Product size 258 Bps
Exon3A-F: [60GC]CTGACGGTGGCCTTGCATAC
Exon3A-R: GTTGTGCAGCGTGGCGATGG
Product size 311 Bps
Exon3B-F: [60GC]ACGAGTTCCGCCTGATGATGACCT
Exon3B-R: AGCCGCGCCTCCTGCAAGCC
Product size 316 Bps
DND-1Exon3B ? C-F: [M13-F]ACGAGTTCCGCCTGATGATGA
DND-1Exon3B ? C-R: [M13-R]AGGTAAGCGGTGGTCGTAG
Product size 527 Bps
Exon4A-F: [60GC]GGGTTTAGACCTGCCCTTGT
Exon4A-R: CGGGCCCAGGGCTGCCCAGCTTCATT
Product size 315 Bps
Exon4B-F: CGGGCCCGGGCTCGGGCTACCCTGCAG
Exon4B-R: [60GC]TTATGCCCATTCAGGGTGCCTG
Product size 407 Bps
F forward primer
R reverse primer
[60GC] = the CG clamp = CGCCCGCCGCGCCCCGCGCCCGG
CCCGCCGCCCCCGCCCGCGCCCGCCGCGCCCCGCGCC
M13-F = CGACGTTGTAAAACGACGGCCAGT
M13-R = CAGGAAACAGCTATGAC
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123unilateral small embryonal carcinoma within a ﬁeld of
carcinoma-in-situ. In his paratesticular tissue a small
mature teratoma was observed. No loss of the wild type
DND1 allele was detected in the patient’s tumors or normal
tissue samples (results not shown). The germline variant
was present in the patient’s healthy father and his 2 healthy
adult brothers, who had no symptoms or history of cancer.
This variant was not detected in the 210 control chromo-
somes. In silico analysis did not predict a pathogenic effect.
Although the amino acid residue at this position is highly
conservedthroughevolution,thesubstitutionfallswithinthe
same class of amino acids (both have negatively charged R
groups, Grantham Score 45). The variant is not located
in any known functional domain (http://www.ncbi.nlm.nih.
gov/Structure/cdd/wrpsb.cgi?seqinput=NP_919225.1).Align
GVGD indicated the p.Asp219Glu missense substitution to
be non-pathogenic (class C0, with a Grantham Variation of
61.28 and a Grantham Deviation of 0.00).
Sorting Intolerant from Tolerance (SIFT) analysis indi-
cated this substitution to be neutral, with a tolerance index
score of 0.73 (normalized probabilities of [0.05 are pre-
dicted to be tolerated). Polyphen classiﬁed the variant as
benign with a PSIC score of 0.498 (scores of \1.5 are
predicted to be benign). This variant has no effect on the
function of the splice acceptor site, nor does it create a
novel splice site (Netgene and Berkeley Drosophila
Genome Project tools).
In addition to the single case of c.657 C[G, two other
variants were detected in our study population. In exon 3,
the silent mutation c.363T[C (p.=) was observed in 172
out of 272 patients (63%); it was homozygous in 60 out of
these 172 patients (35%; 22% of all patients). All the 172
patients were also found to carry an intron 3 variant,
c.604 ? 47G[A. Two other patients only carried this
c.604 ? 47G[A variant. Of the 174 (172 ? 2) patients
who carried this c.604 ? 47G[A variant, 59 (34%;
22% of all patients) were homozygous for it. The NCBI
dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/)
reports a high heterozygosity frequency for both variants:
0.499 for c.363T[C and 0.497 for c.604 ? 47G[A, and
both are regarded as normal population variants.
Discussion
We detected a germline missense c.657 C[G (p.Asp219
Glu)DND1variantinasingleTGCTpatientwithateratoma.
Fromaclinicalpointofview,hisfamilyhistorywasnegative
for cancer and the fact that both his father and brothers carry
the variant suggests either low penetrance or that the variant
makes no contribution to the tumor development. The vari-
antresidesoutsidetheRNAbindingfunctionaldomainofthe
gene and in silico tests indicated non-pathogenicity. In the
TGCT mouse model, homozygous DND1 germline trun-
cating mutations cause total loss of DND1 function. We
thereforetestedourpatient’stumourforlossofthewild type
allele. Both alleles were detected in his tumor samples,
which rules out the possibility of loss of DND1 function
through physical loss of the wild type allele and offers no
evidence for pathogenicity of the observed germline mis-
sense mutation. However, the existence of a somatic muta-
tion in the wild type allele cannot be excluded. The other
variants, c.363T[C and c.604 ? 47G[A, observed fre-
quently in our patients, have been reported as common
polymorphisms by NCBI dbSNP and are not therefore
suspected of contributing to TGCT development. The
p.Glu86AlaDND1variantdetectedinasingleTGCTcaseby
Linger et al. [11] was classiﬁed by these authors as possibly
pathogenic, based on in silico analysis and its absence in
controls.
No functional analysis is currently available to assist in
classifying DND1 missense mutations. Indeed, very little is
known about the role that human DND1 plays in normal
physiology or in disease. The gene has been shown to be
expressed in a range of normal tissues, including testicular
germ cells, Leydig cells, interstitial cells and cells from the
seminiferous tubules [13–15]. Generally, little is known
about expression of DND1 in cancer, but it might be
increased in colorectal adenocarcinoma, leukemia, prostate
cancer, squamous cell carcinoma, and papillary thyroid
cancer [14]. In addition, DND1 maps to a region (5q31.1)
that has been found to be deleted in TGCT [16] and it has
been shown to protect the expression of a range of genes
from repression by miRNAs in primordial germ cells [17].
A role for germline or somatic DND1 mutations in human
cancer, and in particular in TGCT, cannot be ruled out. If it
plays a role, its mechanics may well be complicated since
the genetics of the DND1-mouse-TGCT-model now appear
to be complex [18, 19].
Our study and that of Linger et al. [11] may have a
limitation in that they may have underestimated the fre-
quency of DND1 germline mutations in adult patients. The
presence of most large deletions or duplications, deep
intronic sequence variants, or variants in the regulatory
sequences that might affect gene function could not have
been detected with the methods we and Linger et al used to
Fig. 1 Germline mutation in patient with testicular teratoma.
Sequence of the germline c.657 C[G DND1 mutation detected in
the patient (arrow in lower lane)
DND1 and testicular cancer 441
123analyze the gene. However, the vast majority of germline
mutations in the known human tumor syndromes are trun-
cating mutations, or in some cases missense mutations, e.g.
in Li-Fraumeni syndrome and Multiple Endocrine Neopla-
sia type 2, and these types would have been detected by both
studies. It is therefore reasonable to conclude that germline
DND1 mutations are unlikely to contribute to tumor devel-
opment in the majority of testicular germ cell tumors diag-
nosedinjuvenilesandadults.Whetherthisisalsotrueforthe
very rare group of teratomas and yolk-sac tumors of neo-
nates and infants, that more closely resemble the tumors
observed in mice with germline DND1 mutations, remains
to be investigated.
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